The Epstein-Barr virus is one of the most common and persistent human viruses in the world, according to the CDC.

Reports DescriptionAccording to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is ...

The FDA has approved Gammagard Liquid ERC as a replacement therapy for PI in adult and pediatric patients 2 years of age and older.

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...

Aurinia Pharmaceuticals Inc. has announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a ...

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On ...

Antibodies against SARS-CoV-2 provide protection against infection, but the virus has evolved to evade them. Here, the authors characterize a human antibody with incomplete neutralization of SARS ...

Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies ...